Barton LLP

Barton LLP Featured as “Ones to Watch for 2016: The Best Boutique Law Firms” in Acquisition International Magazine. Click below to read the full article.

Partner Kenneth Rashbaum was recently featured in two articles in the Primerus Paradigm Magazine Winter Edition. The magazine profiles Ken's cybersecurity practice and how it has evolved over the years with the advent of HIPAA, cryptocurrency, and artificial intelligence. The articles also highlight some of Ken's hobbies outside of the legal industry, including long-distance cycling and authoring a novel based on the events of 9/11.

In a recent Bloomberg Law article, Barton Partner Kenneth Rashbaum and co-author Carole Basri provide a road map for organizations that want to use AI tools from third-party providers. They discuss the contract elements and guardrails that should be considered in order to ensure compliance and quality assurance with the deployment of a new AI tool.

Roger E. Barton looks at the ruling in Goldman Sachs Group, Inc. v. Arkansas Teacher Retirement System and examines how it has opened the door for other defendants in certain securities fraud cases to attempt to rebut shareholders’ “presumption of reliance” regarding alleged misleading statements.

Partner Kenneth Rashbaum was recently featured on the Chattinn Cyber podcast, hosted by Marc Schein of Marsh McLennan Agency. In this episode, Ken provides insights into navigating cybersecurity contracts in the current context of a rapidly evolving AI/technology landscape, a fragmented regulatory regime, and differing political philosophies on data privacy legislation. Check out the episode below.

Partner Tara Aaron-Stelluto covers a recent case that dealt with the "fair use" defense for a tech company that was sued for scraping data to train its AI model. The case wrestled with the concept of "transformative" use and highlighted the challenges at the nexus of copyright law and evolving technology.

Barton is proud to announce a slate of new attorneys who have recently joined our firm, as well as the launch of our new Richmond, Virginia office! Read more about our new team members and their practices here: https://lnkd.in/eP_dCUgx

Using or thinking about acquiring AI tools? Contractual (private) governance is the way to establish a strategic partnership with your AI provider. I will be discussing how to use contracts to create sustainable relationships between provider and customer, with Michelle Schaap and Kurt John, at the 2d Life Sciences AI Summit on February 21. Join us to learn how to close deals faster and on the right foot for a sustainable relationship between provider and customer: https://lnkd.in/eDT5qJMC #Lifesciences; #AI; #artificialintelligence

Operations Partner James E. Heavey, Esq. highlights why the mentorship of young financial advisors, as well as proper succession planning by advisors on the brink of retirement, are crucial factors to the prolonged health of the advisory industry.

In 2024, Barton LLP achieved favorable outcomes in two lawsuits brought by Novo Nordisk, the behemoth pharmaceutical company and maker of the blockbuster drugs Ozempic and Wegovy. We we were also able to keep another client from being sued by Eli Lilly, the maker of the competitor drugs Zepbound and Mounjaro. We are now representing another defendant in yet another Novo Nordisk lawsuit. The suits range from claims of false advertising to claims of counterfeit drugs. Novo Nordisk has launched a number of lawsuit campaigns against weight loss clinics and compounding pharmacies over the manufacture and prescription of compounded semaglutide. Semaglutide is the active ingredient and Ozempic and Wegovy and has been widely available from compounding pharmacies since the name brand drugs went on the drug shortage list in 2022. The shortage has not been resolved. Defending lawsuits involving pharmaceutical trademarks involves specialized knowledge of the FDA laws and regulations as well as trademark law. We have that knowledge. We also are quite familiar with Novo Nordisk and their litigation strategy. If you have a client who has been caught up in this latest wave of lawsuits over the use of the Ozempic and Wegovy trademarks or the sale or prescription of compounded semaglutide, please reach out. We are happy to share what we know. Over the next month I'll be talking a lot about pharmaceutical trademark law. Follow along. Novo Nordisk A/S et al v. Indian Lake Medical Weight Loss & Wellness Inc., No 3:2023cv00650 (M.D. Tenn 2024) Novo Nordisk Inc. v. DCA Pharmacy, No. 3:2023cv00668 (M.D. Tenn 2024)